NeOnc Technologies Holdings Inc(NTHI) - 2025 Q2 - Quarterly Report

Financial Performance - The company reported a net loss of $5,680,170 for the three months ended June 30, 2025, compared to a net loss of $4,522,006 for the same period in 2024, representing an increase in loss of $1,158,164[115]. - The company reported a net loss of $38,006,186 for the six months ended June 30, 2025, compared to a net loss of $7,460,982 in 2024, reflecting an increase in losses of 409.5%[144]. - Total operating expenses surged to $37,648,886 for the six months ended June 30, 2025, from $2,894,603 in 2024, an increase of 1,200.5%[144]. - Cash used in operating activities was $10,964,226 for the six months ended June 30, 2025, compared to $172,456 in 2024, indicating a significant increase in cash outflow[156]. - The company generated $39,990 in revenue for the six months ended June 30, 2025, down from $63,000 in 2024, a decrease of 36.6%[144]. Operating Expenses - Total operating expenses for the three months ended June 30, 2025, were $5,708,034, an increase of $4,407,914 compared to $1,300,120 in the same period of 2024[133]. - General and administrative expenses rose to $984,262 for the three months ended June 30, 2025, compared to $289,652 in 2024, marking an increase of 240.5%[136]. - Research and development expenses increased to $677,332 for the three months ended June 30, 2025, from $394,484 in 2024, reflecting an increase of $282,848[133]. - Share-based compensation expense was recorded at $3,526,076 for the three months ended June 30, 2025, with no such expense reported in the same period of 2024[133]. - Legal and professional expenses decreased to $520,364 for the three months ended June 30, 2025, from $590,984 in 2024, a decline of 11.9%[135]. Accumulated Deficit and Financial Position - The company has an accumulated deficit of $88,614,631 as of June 30, 2025[115]. - The company had cash totaling $125,039 at June 30, 2025, raising concerns about its ability to continue as a going concern[162]. Future Funding and Capital Requirements - The company plans to continue funding operations through equity and debt financing, as well as licensing income, to meet future obligations[163]. - The company expects expenses to increase due to ongoing research and development, preclinical studies, and clinical trials, necessitating substantial additional funding[165]. - Future capital requirements will depend on various factors, including the costs of conducting clinical trials and the timing of regulatory reviews[169]. - The company plans to finance operations over the next 12 months primarily through existing cash balances and proceeds from private placements[166]. - If the company raises funds through collaborations or licensing arrangements, it may have to relinquish valuable rights to technologies or future revenue streams[168]. Market and Economic Conditions - The company does not currently face significant market risk related to foreign currency exchange rates, but future fluctuations may occur due to contracts with foreign vendors[171]. - Inflation has not materially affected the company's business or financial condition during the recent reporting periods[172]. Commercialization and Operational Considerations - The company may incur significant commercialization expenses if marketing approval is obtained for product candidates[165]. - Additional debt financing may involve restrictive covenants that could limit operational flexibility[167]. - The company anticipates incurring costs associated with operating as a public company, which will impact overall funding needs[165]. Product Development - The company is developing NEO100 and NEO212, with NEO100 currently in Phase 2a trials and NEO212 having completed preclinical testing[110].